Table 1.
Baseline characteristics of patients with Crohn’s disease (CD) and Ulcerative colitis (UC)
| Patients with CD | Patients with UC | |
|---|---|---|
| Disease duration from initial diagnosis (years) | 12.9 (0.5–44.3) | 8.3 (0.1–51.3) |
| Age at initial diagnosis (years) | 25.5 (10.5–66.8) | 34 (4.0–77.3) |
| Female (%) | 47/75 (63) | 46/106 (43) |
| CRP (mg/L) | 11 (0.2–78.3) | 8.5 (0.2–62.8) |
| Hb (g/dL) | 12.9 (9.1–16.5) | 12.7 (7.5–16.8) |
| Leukocytes × 103/µL | 9.9 (3.6–20) | 9.3 (2.4–22.5) |
| Endoscopic disease activity* | 13.3 (0–26) | 2.3 (0–3) |
| Clinical disease activity** | 7.03 (0–22) | 4 (0–8) |
| Disease extent (%)*** | L1: 15/75 (20) | E1: 7/104 (7) |
| L2: 10/75 (13) | E2: 51/104 (49) | |
| L3: 50/75 (67) | E3: 46/104 (44) | |
| First flare treated with corticosteroids (%) | 63/73 (86) | 86/102 (84) |
| Previous treatment with anti TNF-α antibody (%) | 67/75 (89) | 79/105 (75) |
| Number of previous anti TNF-α antibodies (%) | 1: 14/67 (21) | 1: 43/79 (54) |
| 2: 52/67 (78) | 2: 31/79 (39) | |
| 3: 1/67 (1) | 3: 5/79 (6) | |
| Active smoking (%) | 21/75 (28) | 8/105 (8) |
| Concomitant corticosteroid therapy (%) | 42/74 (57) | 53/101 (52) |
| Concomitant immunosuppressant use (%) | Azathioprin: 3/74 (4) | Azathioprin: 6/102 (6) |
| 6-Mercaptopurin: 0/74 (0) | 6-Mercaptopurin: 2/102 (2) | |
| MTX: 5/74 (7) | MTX: 0/102 (0) | |
| Prior bowel surgery (%) | 22/75 (29) | 1/106 (1) |
| CD phenotype*** (%) | B1: 18/75 (24) | |
| B2: 30/75 (40) | ||
| B3: 27/75 (36) | ||
| Extraintestinal manifestations (%) | 25/75 (33) | 14/106 (13) |
Data are presented as mean (minimal value—maximal value) or frequencies (%)
*Endoscopic Mayo score for UC, simplified endoscopic score for Crohn’s disease (SES-CD) for CD
**PMS (partial Mayo score) for UC, HBI (Harvey Bradshaw-Index) for CD
***According to the Montreal classification